PRDM16 and neoplasm: Luciferase and ChIP assays indicated that PRDM16 exhibits antitumor activities in PTC as a transcription factor through binding to PC promoter, thus inhibiting PC promoter activity at the transcriptional level and further suppressing the EMT process of PTC tumor cells.